Maternal and Neonatal Outcomes in Pregnancies Complicated by Heart Disease: A 5-Year Retrospective Study at a Tertiary Center Hospital in Klang Valley, Malaysia | Chapter 1 | Recent Updates in Disease and Health Research Vol. 5

Background: Maternal heart disease is a leading cause of indirect maternal mortality worldwide similarly in Malaysia with substantially increment in heart disease related. Due to enhanced childhood survival rates, an increasing number of women with congenital heart disease are entering their reproductive years, contributing to an expanding high-risk obstetric group.
 
Aim: To assess the obstetrical and neonatal outcomes among women with maternal heart disease, encompassing both acquired cardiovascular conditions and congenital heart disease.
 
Materials and Methods: This retrospective cross-sectional study involved pregnant women with heart disease at Hospital Serdang from 2014 to 2018. Maternal sociodemographic information, maternal outcomes, and neonatal outcomes were gathered using a proforma from the hospital registry. Data analysis was conducted using SPSS version 25.0.
 
Results: A total of 255 cases of heart disease in pregnancy were collected, with 183 (72%) cases being acquired heart diseases and 72 (28%) cases being congenital heart diseases. A significant correlation was noted between the presence of additional medical comorbidities in expectant mothers, the birth weight of infants, and neonatal admission to the intensive care unit in relation to the type of heart disease in pregnancy.
 
Conclusion: There is a substantial increase in adverse perinatal outcomes. In a rapidly developing country, enhancing the management of pregnant women with heart disease is crucial. This involves improving resources, establishing quality cardiac care facilities, and adopting a collaborative multi-disciplinary team approach. Early cardiac surgical intervention may be beneficial for severe cases, and pre-pregnancy counselling is advised to prevent pregnancy in women with complex diseases, emphasizing the importance of effective contraception for better maternal and neonatal outcomes.

Author(s) Details:

Habibah Abdul Hamid,
Obstetrics & Gynaecology Department, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Karthini Paramasivam,
Obstetrics & Gynaecology Department, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Ameerah Izzati Mohamad Hamsan,
Obstetrics & Gynaecology Department, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Zulida Rejali,
Obstetrics & Gynaecology Department, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

Please see the link here: https://stm.bookpi.org/RUDHR-V5/article/view/14026

Role of Biomarker (Protein S100 β) in Clinical Neurological Assay in Pediatric Patients with Congenital Heart Disease | Chapter 4 | Current Progress in Medicine and Medical Research Vol. 5

 This stage aimed to determine either a correlation exists 'tween S100B serum levels and clinical qualification variables at the pre-operative period of pediatric sufferers with disease of the heart. S100B is a calcium-binding protein, belonging to the S100 family proteins that are characterized by their high solubility and, now, comprises 21 members that are expressed in a cell-particular manner. S100B protein has been projected as a brain injury biomarker in various clinical scenarios. We created a prospective case-control study that included all pediatric inmates (one period to 18 years old), accompanying congenital heart disease, admitted at our organization for surgical treatment, in a 3 month magnitude. We studied 44 patients at the pre-influential period and divided  bureaucracy  in  two  groups:  20 with clinical affecting animate nerve organs background and 24 without bureaucracy. Clinical pediatric neurological background variables were got, and serum levels of S100B protein  were measured utilizing the ELISA “sandwich” method.The  cut-off  for  S100B serum  level  in  victims     with  clinical affecting animate nerve organs background variables was 16 pg/ml, with responsiveness and specificity values of 70%  and  70.8%,  individually.  S100B protein  levels  greater  than  16  pg/ ml correlated accompanying clinical neurological upbringing variables (p=0.014, OR=2.556, and 95% CI=1.205  - 5.418). Neurological clinical background variables before movement may modify active resilience and the risk of affecting animate nerve organs complications. S100B protein appears expected the potential biomarker that we are looking for establishing affecting animate nerve organs morbidity risk at the preoperative period of section for congenital heart disease, due its equating with clinical affecting animate nerve organs background, as shown in this place study.Despite the need of more evidences, our results support a strong trend to contemplate S100B protein as a potential biomarker of clinical neurological culture in pediatric patients accompanying congenital heart disease at the pre-operative ending, because its antitoxin levels > 16pg/ml may predict affecting animate nerve organs damage at a reliably and costless habit before surgery, allowing the clinicians for a more correct neurological support postoperatively in order to advance results.

Author(s) Details:

Luis Antonio Pando-Orellana,

Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico and Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Juan Calderon-Colmenero,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Nancy Lucero Martinez–Rodriguez,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Leonardo Del Valle-Mondragon,

Departamento de Farmacologia, Instituto Nacional de Cardiologia 'Ignacio Chavez', Mexico.

Victor Manuel Espinoza-Gutierrez,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Jorge Luis Cervantes-Salazar,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

 

Juan Verdejo-Paris,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Alfonso Buendia-Hernandez,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

 

Armando Vega-Lopez,

Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico.

 

Pedro Jose Curi-Curi,

Departamento de Cardiologia Pediatrica, Instituto Nacional de Cardiologia “Ignacio Chavez”, Mexico.

Please see the link here: https://stm.bookpi.org/CPMMR-V5/article/view/11384

The Spectrum of Congenital Heart Defects in Infants with Down’s Syndrome, Khartoum, Sudan: A Cross-Sectional Descriptive Study | Chapter 10 | Recent Developments in Medicine and Medical Research Vol. 9

 Using immunohistochemistry for NA, dopamine—hydroxylase (DBH), dopamine (DA), and tyrosine hydroxylase, the location and chemical nature of neurons immunoreactive to noradrenaline (NA) in the cat dorsal vagal complex (DVC) were investigated under various situations. In non-treated animals, the location of NA-immunoreactive (-ir) and DBH-ir neurons was largely overlapping. They were predominantly discovered in the nucleus of solitary tract (NTS), with a few in the dorsal motor nucleus of the vagus. The bulk of NA-ir / DBH-ir neurons were found in the commissural and ventral subnuclei of NTS. In the area postrema, a limited number of weakly stained NA-ir cell bodies coexisted with numerous brightly marked DBH-ir cell bodies. The injection of pargyline, a monoamine oxidase inhibitor (MAOI), increased NA immunoreactivity and the quantity of DVC cells and axons. After treatment with MAOI + parachlorophenylalanine, an inhibitor of tryptophan and phenylalanine hydroxylases, both DA and NA immunoreactivities were dramatically reduced in a large number of axons, while NA immunoreactivity in DVC cell bodies remained visible. NA immunoreactivity was enhanced solely in cell bodies in the areas specified above, where NA and DBH immunoreactivity was weak or undetectable. The physiological repercussions were examined using prior reports as a reference.

Author(S) Details

Osama El-Shazali
Department of Paediatrics, University of Khartoum, Sudan.

View Book:- https://stm.bookpi.org/RDMMR-V9/article/view/4589

Study of Physically Active Children with Congenital Heart Disease | Chapter 14 | Recent Developments in Medicine and Medical Research Vol. 5

 In children with congenital heart disease, advancements in paediatric diagnostic and surgical techniques have had a substantial influence on enhancing survival and lowering death (CHD). Without incident, newborns with tetralogy of Fallot or transposition of the great arteries have reached adulthood with a decent quality of life. The goal of this research is to encourage the continuation of active physiotherapy treatment that began during the inpatient stay. Encourage the incorporation of socio-sports, so that physical activity becomes a part of this population's future lifestyle. The quality of life of operated children has improved, but it is still the goal to maintain physiotherapy treatment after they leave the hospital to avoid musculoskeletal development deficits. This has an impact on their physical state as well as their sports and physical exercise activities. A cardiopulmonary activity test similar to that used in athletes should be used in the follow-up of CHD patients. As a result, the physician will have more knowledge to make better decisions, and the physical education teacher will be able to do his job more safely and devise techniques to help the child perform better. All techniques should be employed, from inspiring the child to making advice to parents, demonstrating that physical activity is an important element of the treatment in both the short and long term.

Author (S) Details

Ricard Serra-Grima

Cardiology Department, Santa Creu and Sant Pau Hospital, IIB Sant Pau, Barcelona, Spain.

Kelly Ferri

FPCEE - Blanquerna, Ramon Llull University, Barcelona, Spain.

Miquel Rissech

Teknon Medical Center, Barcelona, Spain.

View Book :- https://stm.bookpi.org/RDMMR-V5/article/view/4210